|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GNG5 |
Gene summary for GNG5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GNG5 | Gene ID | 2787 |
| Gene name | G protein subunit gamma 5 | |
| Gene Alias | GNG5 | |
| Cytomap | 1p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | P63218 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2787 | GNG5 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.48e-11 | 4.92e-01 | -0.1088 |
| 2787 | GNG5 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.90e-39 | 9.73e-01 | -0.1954 |
| 2787 | GNG5 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.74e-14 | 1.58e+00 | -0.2602 |
| 2787 | GNG5 | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.74e-05 | 7.92e-01 | -0.2196 |
| 2787 | GNG5 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.10e-15 | 8.45e-01 | -0.1207 |
| 2787 | GNG5 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.30e-15 | 9.14e-01 | -0.1526 |
| 2787 | GNG5 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.03e-37 | 9.02e-01 | -0.1464 |
| 2787 | GNG5 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.22e-22 | 5.91e-01 | -0.1001 |
| 2787 | GNG5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.78e-37 | 1.18e+00 | -0.059 |
| 2787 | GNG5 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.01e-09 | 1.01e+00 | -0.1706 |
| 2787 | GNG5 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.84e-18 | 1.07e+00 | -0.2061 |
| 2787 | GNG5 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.08e-12 | 1.07e+00 | -0.1462 |
| 2787 | GNG5 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.13e-13 | 7.21e-01 | -0.0842 |
| 2787 | GNG5 | HTA11_7862_2000001011 | Human | Colorectum | AD | 9.81e-12 | 6.86e-01 | -0.0179 |
| 2787 | GNG5 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.17e-34 | 9.04e-01 | 0.096 |
| 2787 | GNG5 | HTA11_4255_2000001011 | Human | Colorectum | SER | 9.70e-07 | 6.68e-01 | 0.0446 |
| 2787 | GNG5 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.84e-10 | 7.36e-01 | 0.0528 |
| 2787 | GNG5 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.92e-11 | 9.22e-01 | 0.0131 |
| 2787 | GNG5 | HTA11_10623_2000001011 | Human | Colorectum | AD | 6.44e-08 | 5.69e-01 | -0.0177 |
| 2787 | GNG5 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.77e-09 | 9.80e-01 | 0.0171 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
| hsa0472316 | Breast | Precancer | Retrograde endocannabinoid signaling | 25/684 | 148/8465 | 3.05e-04 | 2.47e-03 | 1.89e-03 | 25 |
| hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
| hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
| hsa0472317 | Breast | Precancer | Retrograde endocannabinoid signaling | 25/684 | 148/8465 | 3.05e-04 | 2.47e-03 | 1.89e-03 | 25 |
| hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
| hsa0516723 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
| hsa0472323 | Breast | IDC | Retrograde endocannabinoid signaling | 31/867 | 148/8465 | 7.62e-05 | 7.50e-04 | 5.61e-04 | 31 |
| hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
| hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
| hsa0516733 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
| hsa0472333 | Breast | IDC | Retrograde endocannabinoid signaling | 31/867 | 148/8465 | 7.62e-05 | 7.50e-04 | 5.61e-04 | 31 |
| hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
| hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
| hsa0516743 | Breast | DCIS | Kaposi sarcoma-associated herpesvirus infection | 38/846 | 194/8465 | 3.43e-05 | 3.69e-04 | 2.72e-04 | 38 |
| hsa0472342 | Breast | DCIS | Retrograde endocannabinoid signaling | 29/846 | 148/8465 | 2.82e-04 | 2.34e-03 | 1.72e-03 | 29 |
| hsa0516344 | Breast | DCIS | Human cytomegalovirus infection | 38/846 | 225/8465 | 8.11e-04 | 5.95e-03 | 4.38e-03 | 38 |
| hsa0517024 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
| hsa0516753 | Breast | DCIS | Kaposi sarcoma-associated herpesvirus infection | 38/846 | 194/8465 | 3.43e-05 | 3.69e-04 | 2.72e-04 | 38 |
| hsa0472352 | Breast | DCIS | Retrograde endocannabinoid signaling | 29/846 | 148/8465 | 2.82e-04 | 2.34e-03 | 1.72e-03 | 29 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GNG5 | SNV | Missense_Mutation | c.92N>T | p.Ala31Val | p.A31V | P63218 | protein_coding | tolerated(0.06) | benign(0.424) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| GNG5 | SNV | Missense_Mutation | rs61754630 | c.167C>T | p.Thr56Ile | p.T56I | P63218 | protein_coding | tolerated(0.05) | benign(0.052) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| GNG5 | SNV | Missense_Mutation | c.108A>T | p.Lys36Asn | p.K36N | P63218 | protein_coding | tolerated(0.12) | possibly_damaging(0.673) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |